TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given a consensus rating of “Hold” by the thirteen brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $134.50.

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus lifted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a research note on Tuesday, June 30th. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Finally, Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after acquiring an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after purchasing an additional 938 shares during the last quarter. Finally, M&T Bank Corp acquired a new position in shares of TransMedics Group during the 2nd quarter worth approximately $209,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX opened at $74.29 on Wednesday. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a 50-day simple moving average of $71.23 and a 200-day simple moving average of $103.78. The company has a market capitalization of $2.57 billion, a PE ratio of 16.88 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. During the same period in the prior year, the firm posted $0.70 EPS. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. Equities research analysts predict that TransMedics Group will post 1.88 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.